VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Coutre Discusses Challenges With CAR T-Cell Therapy in ALL

Steven Coutre, MD
Published: Wednesday, Mar 21, 2018



Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Tisagenlecleucel (Kymriah), the first FDA-approved CAR T-cell therapy, is approved for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse. However, it is not approved in adults, and Coutre says that it is not yet known whether CAR T-cell therapy will be used with a curative intent or as a bridge to transplant.

In pediatric patients, investigators are looking to move tisagenlecleucel to earlier lines of therapy. But, if issues with toxicities can be better defined, Coutre says that CAR T-cell therapy may be appropriate for some patients above the current indicated age range.


Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Tisagenlecleucel (Kymriah), the first FDA-approved CAR T-cell therapy, is approved for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse. However, it is not approved in adults, and Coutre says that it is not yet known whether CAR T-cell therapy will be used with a curative intent or as a bridge to transplant.

In pediatric patients, investigators are looking to move tisagenlecleucel to earlier lines of therapy. But, if issues with toxicities can be better defined, Coutre says that CAR T-cell therapy may be appropriate for some patients above the current indicated age range.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x